Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS) was the recipient of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 101,900 shares, a decrease of 21.6% from the January 15th total of 130,000 shares. Based on an average daily volume of 85,200 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.2% of the company’s shares are sold short.

Alpha Tau Medical Stock Performance

DRTS stock traded up $0.08 on Friday, reaching $3.14. The company’s stock had a trading volume of 31,523 shares, compared to its average volume of 148,702. The business has a fifty day simple moving average of $3.39 and a two-hundred day simple moving average of $2.69. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $4.39. The firm has a market cap of $219.55 million, a PE ratio of -7.30 and a beta of 0.83.

Institutional Trading of Alpha Tau Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its position in Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after buying an additional 26,800 shares during the period. Northern Trust Corp lifted its position in Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after buying an additional 25,770 shares during the period. Finally, Levin Capital Strategies L.P. lifted its position in Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after buying an additional 7,189 shares during the period. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Alpha Tau Medical in a research note on Friday, November 22nd.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.